Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2002 Monotherapy and Combination in Advanced Malignant Tumors
NCT05198817Phase 1Unknown
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR-2002 in cancer (4 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Maximum tolerated dose up to 21 days, Recommended phase II dose up to 21 days and 1 more. Status: unknown.
02
Drugs
SHR-2002
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05198817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198817.